depression elderly nursing home

Urinary Incontinence Poses Burden to Long-Term Care

The impact and management of urinary incontinence (UI) related to overactive bladder is a substantial burden to long-term care (LTC) residents and staff, according to a study published online July 1 in the Journal of Gerontological Nursing.  Richard G. Stefanacci, D.O., from Thomas Jefferson University in Philadelphia, and colleagues assessed the impact of UI on residents, staff, care processes, and quality measures in LTC settings. The analysis included responses from directors of nursing who had worked for at least one year in a ≥100-bed facility. Read more.

Source: Health Day News, July 25, 2022

nurse and patient

COVID-19 Infection Increases the Risk of New or Worsening OAB Symptoms

Patients with COVID-19 infection are at increased risk of developing new or worsening symptoms of overactive bladder (OAB), according to data presented at the American Urological Association’s annual meeting in 2022 in New Orleans, Louisiana.  Ly Hoang Roberts, MD, of Oakland University, Royal Oak, Michigan, and colleagues noted that they were the first American group to identify de novo genitourinary symptoms, such as frequency, urgency, nocturia, and pain / pressure in people with previous COVID 19 infection. They called this condition COVID-19 associated cystitis (CAC).  Read more.

Source: Community 99, May 15, 2022

business buildings

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS).  Read more.

Source: Business Wire, March 7, 2022

product approval introduction

Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)

Urovant Sciences, Inc (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. Read more.

Source: BioSpace, December 23, 2020

female doctor

New Research Takes P*** Out of Incontinence

Millions of people might eventually be spared the embarrassment and extreme isolation caused by wetting themselves, thanks to new research. One in every five people has a lower urinary tract disorder called overactive bladder which, for some, means not being able to hold in urine, needing to go to the toilet often, or waking in the night to empty their bladder. Some wear sanitary towels or disposable underwear, while others worry that even with absorbent underwear, they’ll smell of urine, so they choose instead to stay at home. Now, scientists at the University of Portsmouth have identified chemicals in urine that are specific to overactive bladder. The next step is to develop a gadget similar to a pregnancy test, to see if these chemical markers are present. Such a device is 12-24 months from clinical trials, but the early signs are encouraging. Read more.

Source: EurekAlert,, February 20, 2020

product approval introduction

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for the treatment of bladder and bowel dysfunction, today announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration (“FDA”) for the clinical indications of overactive bladder (“OAB”) and urinary retention. The FDA premarket approval (“PMA”) grants Axonics the right to market its product in the United States for the clinical indications of OAB (urinary urge incontinence and urinary urge frequency) as well as urinary retention, representing the largest segment of the market for SNM devices. The FDA approval follows the Company’s September approval for the clinical indication of fecal incontinence, which, according to published clinical studies, is a co-morbidity reported by as many as a third of patients presenting with urinary urge incontinence. Read more.

Source: Business Wire, November 14 2019

drugs for overactive bladder (OAB)

TARIS Bio Initiates New Clinical Study of TAR-302 in Overactive Bladder

TARIS Bio, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, announced today the initiation of a new clinical investigation of TAR-302 for the treatment of overactive bladder (OAB). As a new follow-on arm of the company’s previously concluded Phase 1b trial, the study is designed to investigate the safety, tolerability, and preliminary efficacy of a single 12-week dose of the system, doubling the previous treatment experience and representing a duration that better meets the real-world needs of patients with this serious and chronic disease. Read more.

Source: Yahoo! Finance, May 1, 2019

nurse and patient

AUA Updates Overactive Bladder Guideline

The American Urological Association (AUA) announced that it has updated its guideline for the diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adult patients.  As a result of a 2018 systematic review of recently published studies, AUA modified guideline statement 12 to say clinicians may consider combination therapy with an antimuscarinic agent and beta3-andrenoceptor agonist for patients who are refractory to monotherapy with either of those medications. Read more.

Source: Renal & Urology News, April 25, 2019

drugs for overactive bladder (OAB)

First Big Test Approaches for Urovant

Investors who backed Urovant’s $140m flotation last September will soon find out whether the money was well spent. Before the end of March the company will release topline pivotal data on the overactive bladder project vibegron, a β3-adrenergic receptor agonist licensed from Merck & Co, and a positive result should allow regulatory filings to follow.  It seems likely that the trial will hit: Merck successfully conducted a large phase IIb study of vibegron a few years ago, and a similar compound is already on the market in the shape of Myrbetriq, which has been sold by Astellas since 2011. This well-established product has only four years of US patent life left, so if Urovant has any chance of building vibegron into a similarly large product it needs to prove that its contender is both safer and more effective.   Read more.

Source: Evaluate, March 12, 2019

doctor male discussion

Overactive Bladder Linked to Prostate Cancer ADT

Androgen deprivation therapy (ADT) for prostate cancer is associated with an increased risk of overactive bladder (OAB), a finding consistent with an inhibitory role of androgen in modulating male voiding dysfunction, according to a new study.  Compared with ADT recipients, healthy men and men receiving alpha blockers for benign prostatic hyperplasia (BPH) had a significant 98% and 30% decreased risk of OAB, respectively, after adjusting for numerous potential confounding factors. Increased ADT duration increased the cumulative risk of OAB. Read more.

Source: Renal & Urology News, January 7, 2019